Scott M Stevens

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7175424/publications.pdf

Version: 2024-02-01

64	7,169	236833	143943
papers	citations	25 h-index	57 g-index

67	67	67	8143
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Antithrombotic Therapy for VTE Disease. Chest, 2016, 149, 315-352.	0.4	4,060
2	A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing. New England Journal of Medicine, 2013, 369, 2283-2293.	13.9	660
3	Diagnosis of DVT. Chest, 2012, 141, e351S-e418S.	0.4	570
4	Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. Journal of Thrombosis and Thrombolysis, 2016, 41, 154-164.	1.0	230
5	Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia. Heart Rhythm, 2014, 11, 2206-2213.	0.3	130
6	Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation. American Journal of Cardiology, 2016, 118, 210-214.	0.7	123
7	Withholding Anticoagulation after a Negative Result on Duplex Ultrasonography for Suspected Symptomatic Deep Venous Thrombosis. Annals of Internal Medicine, 2004, 140, 985.	2.0	123
8	Radiation and Chest CT Scan Examinations. Chest, 2012, 142, 750-760.	0.4	110
9	Reduction of Peripherally Inserted Central Catheter-Associated DVT. Chest, 2013, 143, 627-633.	0.4	89
10	Physician Alerts to Prevent Symptomatic Venous Thromboembolism in Hospitalized Patients. Circulation, 2009, 119, 2196-2201.	1.6	88
11	Follow-up of Incidental Pulmonary Nodules and the Radiology Report. Journal of the American College of Radiology, 2014, 11, 378-383.	0.9	86
12	Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 239-247.	0.7	85
13	Adherence to PIOPED II Investigators' Recommendations for Computed Tomography Pulmonary Angiography. American Journal of Medicine, 2013, 126, 36-42.	0.6	70
14	Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. Blood, 2018, 131, 2151-2160.	0.6	62
15	Management of Low-Risk Pulmonary Embolism Patients Without Hospitalization. Chest, 2018, 154, 249-256.	0.4	60
16	Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. Blood Advances, 2022, 6, 1661-1670.	2.5	56
17	Atrial Fibrillation Patients Treated With Longâ€Term Warfarin Anticoagulation Have Higher Rates of All Dementia Types Compared With Patients Receiving Longâ€Term Warfarin for Other Indications. Journal of the American Heart Association, 2016, 5, .	1.6	43
18	Atrial fibrillation incrementally increases dementia risk across all CHADS 2 and CHA 2 DS 2 VASc strata in patients receiving long-term warfarin. American Heart Journal, 2017, 188, 93-98.	1.2	41

#	Article	IF	Citations
19	Protocol Modification of Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome Study. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 192-192.	0.7	41
20	Percent Time With a Supratherapeutic INR in Atrial Fibrillation Patients Also Using an Antiplatelet Agent Is Associated With Longâ€Term Risk of Dementia. Journal of Cardiovascular Electrophysiology, 2015, 26, 1180-1186.	0.8	40
21	The Michigan Appropriateness Guide for Intravenous Catheters (MAGIC) initiative: A summary and review of peripherally inserted central catheter and venous catheter appropriate use. Journal of Hospital Medicine, 2016, 11, 306-310.	0.7	36
22	Longâ€term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to dâ€dimer results; A cohort study. Journal of Thrombosis and Haemostasis, 2019, 17, 1144-1152.	1.9	34
23	Assessment of the Safety and Efficiency of Using an Age-Adjusted D-dimer Threshold to Exclude Suspected Pulmonary Embolism. Chest, 2014, 146, 1444-1451.	0.4	32
24	Major Bleeding With Dabigatran and Rivaroxaban in Patients With Atrial Fibrillation. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 665-672.	0.7	29
25	Follow-up of Incidental Pulmonary Nodules and the Radiology Report. Journal of the American College of Radiology, 2016, 13, R18-R24.	0.9	28
26	Rationale and design of the impact of anticoagulation therapy on the Cognitive Decline and Dementia in Patients with Nonvalvular Atrial Fibrillation (CAF) Trial: A Vanguard study. Clinical Cardiology, 2019, 42, 506-512.	0.7	18
27	Deep Vein Thrombosis Prophylaxis in Hospitalized Medical Patients: Current Recommendations, General Rates of Implementation, and Initiatives for Improvement. Clinics in Chest Medicine, 2010, 31, 675-689.	0.8	16
28	Venous Thromboembolism in Critically Ill Medical Patients Receiving Chemoprophylaxis. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 265-273.	0.7	16
29	Computer surveillance of patients at high risk for and with venous thromboembolism. AMIA ... Annual Symposium proceedings, 2010, 2010, 217-21.	0.2	16
30	Electronic Alerts, Comparative Practitioner Metrics, and Education Improves Thromboprophylaxis and Reduces Thrombosis. American Journal of Medicine, 2016, 129, 1124.e17-1124.e26.	0.6	15
31	Comparative thrombosis risk of vascular access devices among critically ill medical patients. Thrombosis Research, 2018, 172, 54-60.	0.8	15
32	Natural Language Processing Performance for the Identification of Venous Thromboembolism in an Integrated Healthcare System. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110131.	0.7	15
33	Weight-based enoxaparin dosing and deep vein thrombosis in hospitalized trauma patients: A double-blind, randomized, pilot study. Surgery, 2018, 164, 144-149.	1.0	14
34	Age-adjusted versus clinical probability-adjusted D-dimer to exclude pulmonary embolism. Thrombosis Research, 2018, 167, 15-19.	0.8	14
35	Computerized Clinical Decision Support Improves Warfarin Management and Decreases Recurrent Venous Thromboembolism. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 197-203.	0.7	13
36	Electronic alerts, comparative practitioner metrics, and education improve thromboprophylaxis and reduce venous thrombosis in community hospitals. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 481-489.	1.0	12

#	Article	IF	Citations
37	Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty. JAMA - Journal of the American Medical Association, 2019, 322, 834.	3.8	9
38	The use of a fixed high sensitivity to evaluate five D-dimer assays' ability to rule out deep venous thrombosis: a novel approach. British Journal of Haematology, 2005, 131, 341-347.	1.2	8
39	Withholding Anticoagulation Following a Single Negative Whole-Leg Ultrasound in Patients at High Pretest Probability for Deep Vein Thrombosis. Clinical and Applied Thrombosis/Hemostasis, 2013, 19, 79-85.	0.7	8
40	Thrombophilic Evaluation in Patients with Acute Pulmonary Embolism. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 107-120.	0.8	8
41	Diagnosing deep vein thrombosis in cancer patients with suspected symptoms: An individual participant data metaâ€analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 2245-2252.	1.9	6
42	Preemptive Anticoagulation in Patients With a High Pretest Probability of Pulmonary Embolism. Chest, 2018, 153, 1153-1159.	0.4	5
43	Depression as a Driving Force for Low Time in Therapeutic Range and Dementia in Patients With and Without Atrial Fibrillation. American Journal of Cardiology, 2021, 153, 58-64.	0.7	5
44	Intermittent pneumatic compression in patients with stroke. Lancet, The, 2013, 382, 484-486.	6.3	4
45	Role of thrombophilia testing: con. Journal of Thrombosis and Thrombolysis, 2015, 39, 379-391.	1.0	4
46	The Population-Based Long-Term Impact of Anticoagulant and Antiplatelet Therapies in Low-Risk Patients With Atrial Fibrillation. American Journal of Cardiology, 2017, 120, 75-82.	0.7	4
47	Postâ€discharge thrombosis and bleeding in medical patients: A novel risk score derived from ubiquitous biomarkers. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12560.	1.0	4
48	Review: the Wells rule is more useful than individual clinical features for predicting risk of deep venous thrombosis. Evidence-Based Medicine, 2006, 11, 56-56.	0.6	3
49	New evidence on old drugs; warfarin versus aspirin after bioprosthetic aortic valve placement. Thrombosis Research, 2017, 150, 102-103.	0.8	2
50	Predicting postdischarge hospitalâ€associated venous thromboembolism among medical patients using a validated mortality risk score derived from common biomarkers. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 872-878.	1.0	2
51	The Wells rule was not useful in ruling out deep venous thrombosis in a primary care setting. Evidence-Based Medicine, 2006, 11, 57-57.	0.6	1
52	Review: Gestalt or clinical decision rules have limited sensitivity and specificity for detecting acute PE. Annals of Internal Medicine, 2012, 156, JC1.	2.0	1
53	Timing of parenteral anticoagulation after thrombolysis for the treatment of pulmonary embolism. Thrombosis Research, 2020, 195, 58-61.	0.8	1
54	Something old, something newâ€¦. Blood, 2020, 135, 1307-1308.	0.6	1

#	Article	IF	Citations
55	Safety of Excluding Suspected Deep Vein Thrombosis with a Single Whole-Leg Compression Ultrasound: Systematic Review and Meta-Analysis.. Blood, 2009, 114, 243-243.	0.6	1
56	Single Complete Compression Ultrasonography for Suspected Deep Venous Thrombosis: Ideal in Routine Clinical Practice?. Annals of Internal Medicine, 2004, 141, 889.	2.0	1
57	Review: The Wells rule is more useful than individual clinical features for predicting risk for deep venous thrombosis. ACP Journal Club, 2006, 144, 46.	0.1	1
58	Response to Letter Regarding Article, â€œPhysician Alerts to Prevent Symptomatic Venous Thromboembolism in Hospitalized Patientsâ€• Circulation, 2009, 120, .	1.6	0
59	Ultrasound of the Whole Arm to Manage Suspected Upper-Extremity Deep Venous Thrombosis. JAMA Internal Medicine, 2015, 175, 1227.	2.6	0
60	The Wells rule was not useful in ruling out deep venous thrombosis in a primary care setting. ACP Journal Club, 2006, 144, 47.	0.1	0
61	Concomitant VTE increased risks for mortality and hemorrhage in older patients with cancer, with risk varying by cancer type. ACP Journal Club, 2007, 147, 51.	0.1	0
62	Review: the Wells rule is more useful than individual clinical features for predicting risk for deep venous thrombosis. ACP Journal Club, 2006, 144, 46-7.	0.1	0
63	The Wells rule was not useful in ruling out deep venous thrombosis in a primary care setting. ACP Journal Club, 2006, 144, 46-7.	0.1	0
64	Concomitant VTE increased risks for mortality and hemorrhage in older patients with cancer, with risk varying by cancer type. ACP Journal Club, 2007, 147, 51.	0.1	0